PER-001
Phase 2- Indications
- Glaucoma
Company intelligence / Profile preview
Perfuse Therapeutics
San Francisco, California, United Statesperfusetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Perfuse Therapeutics has completed a Phase 1/2a trial for PER-001 in glaucoma patients. The 24-week data showed that PER-001 was well-tolerated and demonstrated proof of concept with both functional and structural improvements. Patients treated with PER-001 on top of IOP reducing therapies experienced a mean improvement in visual field mean deviation of 1 decibel per year and a mean increase in retinal nerve fiber layer thickness of 3 microns at 24 weeks. The Phase 2a Dose 2 cohort is ongoing with topline data expected in Q2 2025.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculesSustained release drug delivery
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Perfuse Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Perfuse Therapeutics.